Miyoung Park

Dr. Miyoung Park


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
CPChun Wook Park
Chun Wook Park
BKBeom Joon Kim
Beom Joon Kim
YLYang Won Lee
Yang Won Lee
CWChonghyun Won
Chonghyun Won
CPChang Ook Park
Chang Ook Park
MPMiyoung Park
Miyoung Park
Asivatrep is a potent and selective antagonist of transient receptor potential vanilloid subfamily V member 1 (TRPV1), which plays an important role in itch and inflammation in atopic dermatitis (AD). This current study aimed to evaluate the efficacy and safety of asivatrep cream in patients with AD. For this phase 3 double-blind, vehicle-controlled study, patients aged ≥12 years with mild to moderate AD were enrolled and randomly assigned 2:1 to the 1.0% asivatrep or vehicle group for 8 weeks of twice-daily application (n = 240). The primary end point was the proportion of patients with an Investigator's Global Assessment score (IGA) of 0 or 1 at week 8. Standard safety assessments were conducted. At week 8, significantly more patients in the asivatrep group (36.0%) than in the vehicle group (12.8%) had IGA scores of 0 or 1 (P < .001); significantly more had ≥2 points of improvement on the IGA from baseline score (20.3% vs 7.7%; P = .01). The mean percentage reduction in the Eczema Area and Severity Index (EASI) score was 44.3% for the asivatrep group and 21.4% for the vehicle group at week 8 (P < .001). Significantly more asivatrep-treated patients experienced an improvement of at least 50%, 75%, and 90% on the EASI than the vehicle group. The mean ± SD change in the pruritus visual analog scale score at week 8 was -2.3 ± 2.4 for the asivatrep group and -1.5 ± 2.4 for the vehicle group (P = .02). No significant safety issues were reported. Asivatrep improved clinical signs and symptoms of AD and was well tolerated.

26 January 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JKJuewon Kim
Juewon Kim
HCHyunjung Choi
Hyunjung Choi
DCDong-Hwa Choi
Dong-Hwa Choi
KPKyuhee Park
Kyuhee Park
HKHyung-June Kim
Hyung-June Kim
MPMiyoung Park
Miyoung Park
Airborne fine dust particles (FDPs) have been identified as major toxins in air pollution that threaten human respiratory health. While searching for an anti-FDP reagent, we found that green tea extract (GTE) and fractions rich in flavonol glycosides (FLGs) and crude tea polysaccharides (CTPs) had protective effects against FDP-stimulated cellular damage in the BEAS-2B airway epithelial cell line. The GTE, FLGs, and CTPs significantly increased viability and lowered oxidative stress levels in FDP-treated cells. Combined treatment with GTE, FLGs, and CTPs also exerted synergistic protective effects on cells and attenuated FDP-induced elevations in inflammatory gene expression. Moreover, the green tea components increased the proportion of ciliated cells and upregulated ciliogenesis in the airway in FDP-stimulated BEAS-2B cells. Our findings provide insights into how natural phytochemicals protect the airway and suggest that green tea could be used to reduce FDP-induced airway damage as an ingredient in pharmaceutical, nutraceutical, and also cosmeceutical products.

28 February 2021 in Journal of the Korean Society of Food Science and Nutrition
Verified
Journal Article
Open access
PDF file
JLJi-Hae Lee
Ji-Hae Lee
MCMinjung Chae
Minjung Chae
JCJin Kyu Choi
Jin Kyu Choi
WKWangi Kim
Wangi Kim
MPMiyoung Park
Miyoung Park
Ji-Hae Lee, Minjung Chae, Jin Kyu Choi, Wangi Kim, and Miyoung Park. Journal of the Korean Society of Food Science and Nutrition 2021;50:119-27. https://doi.org/10.3746/jkfn.2021.50.2.119